Nadroparin calcium

Nadroparin calcium is an oligosaccharide pharmaceutical. It is currently being investigated in clinical studies.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

54 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Injection site reaction	D000075662	—	—	—	—	—	1	—	1

Indications Phases 3

No data

Indications Phases 2

No data

Indications Phases 1

No data

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Nadroparin calcium
INN	nadroparin calcium
Description	Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.
Classification	Oligosaccharide
Drug class	heparin derivatives and low molecular weight (or depolymerized) heparins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—